• Confocal imaging of paraffin-embedded Rat heart using alpha Sarcoglycan (SGCA) Rabbit monoclonal antibody (STJ11103115, dilution 1:100) followed by a further incubation with Cy3 Goat Anti-Rabbit IgG (H+L) ( dilution 1:500) (Red). DAPI was used for nuclear staining (Blue). Objective: 40x. Perform high pressure antigen retrieval with 0. 01 M citrate buffer (pH 6. 0) prior to IF staining.
  • Confocal imaging of paraffin-embedded Mouse heart using alpha Sarcoglycan (SGCA) Rabbit monoclonal antibody (STJ11103115, dilution 1:100) followed by a further incubation with Cy3 Goat Anti-Rabbit IgG (H+L) ( dilution 1:500) (Red). DAPI was used for nuclear staining (Blue). Objective: 40x. Perform high pressure antigen retrieval with 0. 01 M citrate buffer (pH 6. 0) prior to IF staining.
  • Immunohistochemistry analysis of alpha Sarcoglycan (SGCA) in paraffin-embedded rat heart using alpha Sarcoglycan (SGCA) (SGCA) Rabbit monoclonal antibody (STJ11103115) at dilution of 1:100 (40x lens). Perform microwave antigen retrieval with 10 mM Tris/EDTA buffer pH 9. 0 before commencing with immunohistochemistry staining protocol.
  • Immunohistochemistry analysis of alpha Sarcoglycan (SGCA) in paraffin-embedded mouse heart using alpha Sarcoglycan (SGCA) (SGCA) Rabbit monoclonal antibody (STJ11103115) at dilution of 1:100 (40x lens). Perform microwave antigen retrieval with 10 mM Tris/EDTA buffer pH 9. 0 before commencing with immunohistochemistry staining protocol.
  • Western blot analysis of various lysates using alpha Sarcoglycan (SGCA) (SGCA) Rabbit monoclonal antibody (STJ11103115) at 1:500 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 10s.

Anti-alpha Sarcoglycan antibody (288-387) [S5MR] (STJ11103115)

SKU:
STJ11103115

£146.50 - £639.50
Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB/IHC/IF
Reactivity: Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit monoclonal antibody anti-alpha Sarcoglycan (SGCA) (288-387) is suitable for use in Western Blot, Immunohistochemistry and Immunofluorescence research applications.
Clonality: Monoclonal
Clone ID: S5MR
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 0.05% BSA, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:100-1:500
IHC-P 1:50-1:200
IF/ICC 1:50-1:200
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: SGCA
Gene ID: 6442
Uniprot ID: SGCA_HUMAN
Immunogen Region: 288-387
Immunogen: A synthetic peptide corresponding to a sequence within amino acids 288-387 of human alpha Sarcoglycan (SGCA) (SGCA) (Q16586).
Immunogen Sequence: VDALVTLLVPLLVALLLTLL LAYVMCCRREGRLKRDLATS DIQMVHHCTIHGNTEELRQM AASREVPRPLSTLPMFNVHT GERLPPRVDSAQVPLILDQH
Tissue Specificity Most strongly expressed in skeletal muscle. Also expressed in cardiac muscle and, at much lower levels, in lung. In the fetus, most abundant in cardiac muscle and, at lower levels, in lung. Also detected in liver and kidney. Not expressed in brain.
Function Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix.
Protein Name Alpha-Sarcoglycan
Alpha-Sg
50 Kda Dystrophin-Associated Glycoprotein
50dag
Adhalin
Dystroglycan-2
Cellular Localisation Cell Membrane
Sarcolemma
Single-Pass Type I Membrane Protein
Cytoplasm
Cytoskeleton
Alternative Antibody Names Anti-Alpha-Sarcoglycan antibody
Anti-Alpha-Sg antibody
Anti-50 Kda Dystrophin-Associated Glycoprotein antibody
Anti-50dag antibody
Anti-Adhalin antibody
Anti-Dystroglycan-2 antibody
Anti-SGCA antibody
Anti-ADL antibody
Anti-DAG2 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance